Xlife Sciences AG (SWX:XLS)
Switzerland · Delayed Price · Currency is CHF 23.00
+0.90 (4.07%)
At close: Jan 30, 2026
Xlife Sciences AG Revenue
Xlife Sciences AG had revenue of 354.32K CHF in the half year ending June 30, 2025, with 1.82% growth. This brings the company's revenue in the last twelve months to 839.38K, down -15.24% year-over-year. In the year 2024, Xlife Sciences AG had annual revenue of 834.88K, down -15.54%.
Revenue (ttm)
839.38K
Revenue Growth
-15.24%
P/S Ratio
158.04
Revenue / Employee
49.38K
Employees
17
Market Cap
132.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 834.88K | -153.56K | -15.54% |
| Dec 31, 2023 | 988.44K | -39.54K | -3.85% |
| Dec 31, 2022 | 1.03M | 221.91K | 27.53% |
| Dec 31, 2021 | 806.07K | 409.26K | 103.14% |
| Dec 31, 2020 | 396.81K | -118.02K | -22.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 236.21M |
| Idorsia | 232.51M |
| Newron Pharmaceuticals | 55.93M |
| Santhera Pharmaceuticals Holding AG | 49.02M |
| BioVersys AG | 1.31M |
| Molecular Partners AG | 681.00K |
| Addex Therapeutics | 158.54K |